The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

31 Jan 2012 14:00

RNS Number : 4971W
Byotrol PLC
31 January 2012
 



 

31 January 2012

 

 

Byotrol plc

Commercial and Trading Update including

Rentokil Initial UltraProtect™ product launch and extension of agreement with Fortune 150 partner

 

 

Byotrol plc ('Byotrol' or the "Company"), the developer of anti microbial hygiene technologies, is pleased to provide a commercial and trading update.

 

Following an extensive development process by partners Byotrol and Rentokil Initial plc ('Rentokil Initial'), Rentokil Initial last week formally launched the UltraProtect™ range, powered by Byotrol, under the contract announced in July 2011. UltraProtect™ is a range of hand and surface sanitising products for commercial and public use, featuring a gel hand sanitiser, a foam hand sanitiser, and handy packs of hand and surface wipes. 

 

Rentokil Initial is one of the largest business services companies in the world, operating in the major economies of Europe, North America, Asia Pacific and Africa. Plans are underway to introduce UltraProtect™ across Europe in 2012. It is expected that the new revolutionary sanitiser will be available in more than ten countries - beginning with the UK and then France and Germany in the coming weeks. This exclusive range of products will target a number of key markets including the commercial, medical, hospitality & leisure and education sectors. 

 

Peter Slator, Divisional Managing Director at Rentokil Initial commented:

 

"Our new range of surface and hand hygiene products, powered by Byotrol's unique technology, will be a valuable element in achieving Initial's objective of 'Raising Hygiene Standards' throughout our customers' organisations. It will give our customers access to a pioneering hygiene solution and enable us to penetrate new markets."

 

 

In addition, through Byotrol Consumer Products Limited ('BCP'), Byotrol is pleased to announce that it has agreed terms for a six month extension of the Joint Development Agreement ('JDA') with their Fortune 150 partner company, for which BCP will receive $300,000. This follows the successful completion of all technical milestones and the successful assessment of Byotrol's technology performance in the plan referred to in the JDA announced in May 2011. The two companies will now complete consumer research and commercial analysis with the aim of a decision on a full commercial agreement.

 

The Board of Byotrol is pleased to report these significant commercial developments achieved within the last six months, which are transforming Byotrol into a better quality, more sustainable, business. There have, however, been some delays in anticipated launch dates, and additional investment of development time, as Byotrol seeks to maximise its potential margins and focus on better quality, more repeatable business. These delays will have an impact on the results for the financial year ending 31 March 2012. Revenue for the 12 months to 31 March 2012 is now expected to be approximately £2.0m with a consequent effect on the trading loss for the year.

 

The Company anticipates having cash of £1.2m at 31 March 2012 and still expects to be trading profitably by the year ending 31 March 2013.

 

Commenting on the current developments, Gary Millar, CEO of Byotrol, said:

 

"Byotrol is at a very exciting phase in its development. In particular the launch of UltraProtect™ is tremendously positive and will demonstrate the breadth of success that Byotrol products can achieve through partnering with established industry suppliers with global reach. We will continue to work actively on our long term relationship with Rentokil Initial, in addition to other selected partners, to achieve a rapid increase in our market penetration.

 

"I am also delighted that we have successfully achieved all the technical milestones envisaged with our Fortune 150 consumer products partner and look forward to the extension of our joint development agreement.

 

"The complex nature of the projects involved in generating more repeatable, better quality revenues, has resulted in some delays in expected launch dates and as a result our revenues for the 12 months to 31 March 2012 will be lower than expected. I am confident that we now have a better quality business with strong partners that will lead to sustained growth for the future."

 

 

Enquiries:

 

Byotrol plc

Gary Millar - Chief Executive

Richard Bell - Finance Director

 

finnCap

Geoff Nash/Christopher Raggett - Corporate Finance

Tom Jenkins/Simon Starr - Corporate Broking

 

Winningtons

Tom Cooper/Paul Vann

01925 742 000

 

 

 

020 7220 0500

 

 

020 3176 4722

0797 122 1972

tom.cooper@winningtons.co.uk

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae.

 

The Byotrol product can be used as a standalone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTXFLFXLFFXBBF
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.